Adverse drug effects are a reported reason for treatment discontinuation and loss to follow-up among pulmonary tuberculosis patients.

the verdict

SUPPORTED

the evidence backs this

Recorded sources

5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that adverse drug effects are a reported reason for treatment discontinuation and loss to follow-up among pulmonary tuberculosis patients?

Yes. Adverse drug effects are frequently documented as a major cause of treatment interruption, discontinuation, and loss to follow-up among pulmonary tuberculosis patients.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked 3 Oct 2026

The analysis

Multiple literature reviews, clinical studies, and patient surveys consistently report that adverse drug reactions during antituberculosis therapy lead to treatment interruptions, discontinuation, and loss to follow-up.

Evidence for · 5

The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.

2025

The review notes that adverse reactions from tuberculosis drugs lead to treatment interruptions and decreased adherence.

Get citation

R, M. & E, D. (2025). The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.. doi.org. https://doi.org/10.3390/medicina61050911

See more details

More for · 4

Therapy-induced cardiotoxicity in drug-resistant tuberculosis patients: A systematic review and meta-analysis.

2025

The meta-analysis highlights that antituberculosis regimens carry cardiotoxicity concerns that result in treatment discontinuation.

Get citation

LD, L., K, K., HM, L., & A, P. (2025). Therapy-induced cardiotoxicity in drug-resistant tuberculosis patients: A systematic review and meta-analysis.. doi.org. https://doi.org/10.21542/gcsp.2025.53

Isoniazid-induced alopecia in isoniazid-monoresistant pulmonary tuberculosis.

2026

A case report describes a patient who stopped tuberculosis treatment due to alopecia caused by isoniazid.

Get citation

E, A., Ş, Ö., & FC, G. (2026). Isoniazid-induced alopecia in isoniazid-monoresistant pulmonary tuberculosis.. doi.org. https://doi.org/10.1186/s12890-026-04150-0

User needs and design opportunities for a conversational agent for tuberculosis treatment: A mixed-methods study.

2026

Survey data from healthcare professionals and patients identify adverse drug reactions as key challenges and reported reasons for discontinuation or consultation needs.

Get citation

JS, B., S, C., S, S., V, R., & Y, P. (2026). User needs and design opportunities for a conversational agent for tuberculosis treatment: A mixed-methods study.. doi.org. https://doi.org/10.1371/journal.pdig.0001720

Effectiveness and challenges of DOT in multidrug-resistant TB: a 12-year retrospective study.

2026

A 12-year retrospective study notes that treatment-related side effects contribute to patient loss to follow-up.

Get citation

S, J., S, M., F, R., N, A., MN, K., SM, Q., M, A., N, A., AW, K., Y, F., & F, Z. (2026). Effectiveness and challenges of DOT in multidrug-resistant TB: a 12-year retrospective study.. doi.org. https://doi.org/10.5588/pha.25.0057

What does the evidence say?

Receipt History

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work